Abstract
Introduction
This study examines the role of mesenchymal stem cells (MSCs) in an experimental sepsis model developed with colistin-resistant Acinetobacter baumannii (CRAB).
Materials and methods
BALB-c mice were divided into treatment groups (MSC, MSC + colistin (C)-fosfomycin (F), and C-F and control groups (positive and negative)). CRAB was administered to mice through intraperitoneal injection. Three hours later, C, F, and MSC were given intraperitoneally to the treatment groups. Colistin administration was repeated every 12 h, F administration was done every 4 h, and the second dose of MSC was administered after 48 h. Mice were sacrificed at 24 and 72 h. The bacterial load was determined as colony-forming units per gram (cfu/g). Histopathological examination was conducted on the left lung, liver, and both kidneys. IL-6 and C-reactive protein (CRP) levels in mouse sera were determined by enzyme-linked immunosorbent assay.
Results
Among the treatment groups, the C-F group had the lowest colony count in the lung (1.24 ± 1.66 cfu/g) and liver (1.03 ± 1.08 cfu/g). The highest bacterial clearance was observed at 72 h compared to 24 h in the MSC-treated groups (p = 0.008). The MSC + C-F group showed the lowest histopathological score in the liver and kidney (p = 0.009). In the negative control group, the IL-6 level at the 24th hour was the lowest (p < 0.001). Among the treatment groups, the CRP level was the lowest in the MSC + C-F group at 24 and 72 h.
Conclusion
In a CRAB sepsis model, adding MSCs to a colistin-fosfomycin treatment may be beneficial in terms of reducing bacterial loads and preventing histopathological damage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Not applicable.
References
Gönen ZB, Dinç G, Doğanay M (2020) Mesenchymal stem cell therapy for severe sepsis and septic shock. Erciyes Med J 42(1):1–2. https://doi.org/10.14744/etd.2019.35336
Chiu C, Legrand M (2021) Epidemiology of sepsis and septic shock. Curr Opin Anaesthesiol 34(2):71–76. https://doi.org/10.1097/ACO.0000000000000958
Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA et al (2022) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 28(4):521–547. https://doi.org/10.1016/j.cmi.2021.11.025
Karakonstantis S, Kritsotakis EI, Gikas A (2020) Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother 75(2):271–282. https://doi.org/10.1093/jac/dkz401
Karakonstantis S, Gikas A, Astrinaki E, Kritsotakis EI, Karakonstantis S, Gikas A et al (2020) Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients. J Hosp Infect 106(3):447–453. https://doi.org/10.1016/j.jhin.2020.09.009
Saelim W, Changpradub D, Thunyaharn S, Juntanawiwat P, Nulsopapon P, Santimaleeworagun W (2021) Colistin plus sulbactam or fosfomycin against carbapenem-resistant Acinetobacter baumannii: improved efficacy or decreased risk of nephrotoxicity? Infect Chemother 53(1):128–140. https://doi.org/10.3947/ic.2021.0007
Leelasupasri S, Santimaleeworagun W, Jitwasinkul T (2018) Antimicrobial susceptibility among colistin, sulbactam, and fosfomycin and a synergism study of colistin in combination with sulbactam or fosfomycin against clinical isolates of carbapenem-resistant Acinetobacter baumannii. J Pathog 2018:3893492. https://doi.org/10.1155/2018/3893492
Abdul-Mutakabbir JC, Griffith NC, Shields RK, Tverdek FP, Escobar ZK (2021) Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the Society of Infectious Diseases Pharmacists. Infect Dis Ther 10(4):2177–2202. https://doi.org/10.1007/s40121-021-00541-4
Zheng G, Huang R, Qiu G, Ge M, Wang J, Shu Q et al (2018) Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis. Cell Tissue Res 374(1):1–15
Keane C, Jerkic M, Laffey JG (2017) Stem cell-based therapies for sepsis. Anesthesiology 127(6):1017–1034. https://doi.org/10.1097/ALN.0000000000001882
Lombardo E, van der Poll T, DelaRosa O, Dalemans W, Lombardo E, van der Poll T et al (2015) Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells 7(2):368–379. https://doi.org/10.4252/wjsc.v7.i2.368
Alp E, Gonen ZB, Gundogan K, Esmaoglu A, Kaynar L, Cetin A et al (2022) The effect of mesenchymal stromal cells on the mortality of patients with sepsis and septic shock: a promising therapy. Emerg Med Int 2022:9222379
European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 12.0, valid from 2022-01-01. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf. Accessed 02.08.2023
Eryılmaz-Eren E, Dinç G, Kontaş O, Alp E, Doğanay M (2021) The investigation of adrenal involvement in carbapenem resistant Acinetobacter baumannii sepsis: experimental mouse model. Turk J Med Sci 51(6):3108–3114. https://doi.org/10.3906/sag-2001-163
The Clinical and Laboratory Standards Institute 2020 [İnternet]. [a.yer 27 Şubat 2022]. Erişim adresi. https://www.nih.org.pk/wp-content/uploads/2021/02/CLSI-2020.pdf. Accessed 27 Feb 2022
Ku NS, Lee SH, Soun LY, Choi H, Ahn JY, Jeong SJ et al (2019) In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia. Sci Rep 9(1):17127. https://doi.org/10.1038/s41598-019-53714-0
Dinc G, Demiraslan H, Elmali F, Ahmed SS, Alp E, Doganay M (2015) Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii. New Microbiol 38(1):67–73
Nwabor OF, Terbtothakun P, Voravuthikunchai SP, Chusri S, Nwabor OF, Terbtothakun P et al (2021) Evaluation of the synergistic antibacterial effects of fosfomycin in combination with selected antibiotics against carbapenem-resistant Acinetobacter baumannii. Pharmaceuticals (Basel). 14(3):185. https://doi.org/10.3390/ph14030185
Sirijatuphat R, Thamlikitkul V, Sirijatuphat R, Thamlikitkul V (2014) Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 58(9):5598–5601. https://doi.org/10.1128/AAC.02435-13
Marrazzo P, Crupi AN, Alviano F, Teodori L, Bonsi L (2019) Exploring the roles of MSCs in infections: focus on bacterial diseases. J Mol Med (Berl) 97(4):437–450. https://doi.org/10.1007/s00109-019-01752-6
Alcayaga-Miranda F, Cuenca J, Martin A, Contreras L, Figueroa FE, Khoury M (2015) Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis. Stem Cell Res Ther 6:199
Galstyan G, Makarova P, Parovichnikova E, Kuzmina L, Troitskaya V et al (2018) The results of the single center pilot randomized Russian Clinical Trial of Mesenchymal Stromal Cells in Severe Neutropenic Patients with Septic Shock (RUMCESS). Int J Blood Res Disord 5:033. https://doi.org/10.23937/2469-5696/1410033
Fazekas B, Alagesan S, Watson L, Ng O, Conroy CM, Català C et al (2022) Comparison of single and repeated dosing of anti-inflammatory human umbilical cord mesenchymal stromal cells in a mouse model of polymicrobial sepsis. Stem Cell Rev Rep 18(4):1444–1460. https://doi.org/10.1007/s12015-021-10323-7
Luo CJ, Zhang FJ, Zhang L, Geng YQ, Li QG, Hong Q et al (2014) Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. Shock 41(2):123–129. https://doi.org/10.1097/SHK.0000000000000080
Yang CC, Sung PH, Chen CH, Chiang JY, Shao PL, Wu SC et al (2021) Additional benefit of induced pluripotent stem cell-derived mesenchymal stem cell therapy on sepsis syndrome-associated acute kidney injury in rat treated with antibiotic. Stem Cell Res Ther 12(1):526. https://doi.org/10.1186/s13287-021-02582-5
Hackstein H, Lippitsch A, Krug P, Schevtschenko I, Kranz S, Hecker M et al (2015) Prospectively defined murine mesenchymal stem cells inhibit Klebsiella pneumoniae-induced acute lung injury and improve pneumonia survival. Respir Res 16:123. https://doi.org/10.1186/s12931-015-0288-1
Devaney J, Horie S, Masterson C et al (2015) Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax. 70(7):625–635. https://doi.org/10.1136/thoraxjnl-2015-206813
He X, Ai S, Guo W, Yang Y, Wang Z, Jiang D et al (2018) Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: aphase 1 clinical trial. Transl Res 199:52–61. https://doi.org/10.1016/j.trsl.2018.04.006
Gonzalez H, Keane C, Masterson CH, Horie S, Elliman SJ, Higgins BD et al (2020) Umbilical cord-derived CD362+ mesenchymal stromal cells attenuate polymicrobial sepsis induced by caecal ligation and puncture. Int J Mol Sci 21(21):8270. https://doi.org/10.3390/ijms21218270
Perlee D, de Vos AF, Scicluna BP, Mancheño P, de la Rosa O, Dalemans W et al (2019) Human adipose-derived mesenchymal stem cells modify lung immunity and improve antibacterial defense in pneumosepsis caused by Klebsiella pneumoniae. Stem Cells Transl Med. 8(8):785–796. https://doi.org/10.1002/sctm.18-0260
Petryk N, Shevchenko O (2020) Mesenchymal stem cells anti-inflammatory activity in rats: proinflammatory cytokines. J Inflamm Res 13:293–301. https://doi.org/10.2147/JIR.S256932
Funding
The Erciyes University Scientific Research Project Unit provided funding for this study (Project No: TTU-2021-10624)
Author information
Authors and Affiliations
Contributions
Fİ, ZT, GD, EE, AHY, DB, and ZBG performed the analysis, collect the data, and prepare material; Fİ, ZT, and GK: collect the patient data; Fİ and ZT wrote the paper; Fİ, ZT, GD, GKÜ, BA, and OY made the critical reviews. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the Ethical Committee of the University of Erciyes; all subject provided written informed consent (03.06.2020- 20/089).
Consent to participate
Not applicable.
Consent for publication
All the authors reviewed and approved the final version of the manuscript.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
İzci, F., Ture, Z., Dinc, G. et al. The efficacy of mesenchymal stem cell treatment and colistin-fosfomycin combination on colistin-resistant Acinetobacter baumannii sepsis model. Eur J Clin Microbiol Infect Dis 42, 1365–1372 (2023). https://doi.org/10.1007/s10096-023-04674-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-023-04674-x